Share on LinkedInShare on LinkedIn

ARTICLE · 06 AUGUST 2015

Sowing Uncertainty: Navigating Patent Disputes And Antitrust Scrutiny Post King Drug

On June 26, 2015, the Third Circuit issued an opinion in King Drug Co. of Florence, Inc. v. Smithkline Beecham Corp., (Case No. 14-1243).

United StatesAntitrust/Competition Law

On June 26, 2015, the Third Circuit issued an opinion in King Drug Co. of Florence, Inc. v. Smithkline Beecham Corp., (Case No. 14-1243). King Drug. The opinion, which already has been extensively commented on and scrutinized, purports to follow the Supreme Court's holding in FTC v. Acatvis, Inc. Actavis holds that patent dispute settlements consisting of reverse cash payments from a brand drug manufacturer to a generic drug manufacturer are subject to rule of reason scrutiny. King Drug holds that, similarly, non-cash settlements in which a patentee drug manufacturer agrees to relinquish its right to produce an "authorized generic" of the drug (a "no-AG agreement") to compete with a first-filing generic drug's 180-day exclusivity period, are subject to antitrust scrutiny under a "rule of reason analysis."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from